An Open-Label, Randomized, Multi-Center, Single Dose, Two-Period, Two Sequence Crossover Study to Investigate the Bioequivalence of Peginterferon (PEG-IFN) Alfa-2a Benzyl Alcohol-Free Formulation Versus the Reference Market Formulation Following Subcutaneous Administration Via Prefilled Syringe in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2016 Status changed from active, no longer recruiting to completed.
- 01 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.